AIM: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice. METHODS: Retrospective study of atrial fibrillation patients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga). RESULTS: A total of 111 patients (mean age 74.9 ± 10.9 years; 52.3% men; CHA2DS2-VASc 3.6 ± 1.3; HAS-BLED 1.3 ± 0.6) were included. A total of 96.3 and 90.6% of patients remained on rivaroxaban therapy after 1 and 2 years of treatment, respectively. During this period, stroke, net clinical benefit outcome (thromboembolic events, myocardial infarction, cardiovascular death and major bleeding) and cardiovascular death occurred in 3.6, 5.4 and 1.8% of patients, respectively. CONCLUSION: In routine practice, medication persistence with rivaroxaban was high. Rates of major cardiac events were low.
AIM: To evaluate medication persistence and outcomes in patients with atrial fibrillation after 2 years of treatment with rivaroxaban in routine practice. METHODS: Retrospective study of atrial fibrillationpatients in whom rivaroxaban was prescribed during the first quarter of 2014 in the healthcare area of Costa del Sol (Málaga). RESULTS: A total of 111 patients (mean age 74.9 ± 10.9 years; 52.3% men; CHA2DS2-VASc 3.6 ± 1.3; HAS-BLED 1.3 ± 0.6) were included. A total of 96.3 and 90.6% of patients remained on rivaroxaban therapy after 1 and 2 years of treatment, respectively. During this period, stroke, net clinical benefit outcome (thromboembolic events, myocardial infarction, cardiovascular death and major bleeding) and cardiovascular death occurred in 3.6, 5.4 and 1.8% of patients, respectively. CONCLUSION: In routine practice, medication persistence with rivaroxaban was high. Rates of major cardiac events were low.
Authors: Marcelo Sanmartín Fernández; Manuel Anguita Sánchez; Fernando Arribas; Gonzalo Barón-Esquivias; Vivencio Barrios; Juan Cosin-Sales; María Asunción Esteve-Pastor; Roman Freixa-Pamias; Iñaki Lekuona; Alejandro I Pérez-Cabeza; Isabel Ureña; José Manuel Vázquez Rodríguez; Carles Rafols Priu; Francisco Marin Journal: Cardiol J Date: 2022-05-27 Impact factor: 3.487